What is IGF-1 LR3? A modified variant of insulin-like growth factor 1 with lower affinity for the carrier proteins, a change that considerably extends its half-life and its systemic activity.
This is the compound in the catalog that demands the most caution, and the article is written accordingly: it describes what is known, states plainly what is not, and offers no guidance on use.
Native IGF-1 and its role in the GH axis
IGF-1 is the main mediator of growth hormone's effects. GH acts on the liver and other tissues, and those tissues produce IGF-1, which carries out much of the anabolic activity credited to the axis.
Two features of its normal physiology matter here:
It circulates bound to carrier proteins. More than 95% of the IGF-1 in blood travels bound to the IGFBPs, the binding proteins, mostly to IGFBP-3 as a ternary complex. Only the free fraction is biologically active.
It takes part in the axis feedback loop. Elevated IGF-1 slows GH production. That is the control mechanism that keeps the system from running away.
What the LR3 variant actually changes
So what is IGF-1 LR3, chemically? LR3 stands for Long R3: the molecule carries two modifications relative to human IGF-1.
- A 13-amino-acid extension at the N-terminal end.
- A substitution at position 3, arginine in place of glutamic acid.
The combined effect is a sharply reduced affinity for the carrier proteins. From there follow the two consequences that define the compound:
The half-life multiplies. Free native IGF-1 has a half-life of minutes; bound to IGFBP-3, of hours. The LR3 variant is never sequestered, so it stays active far longer.
The active fraction is much larger. Practically the whole administered molecule is available to bind receptors, instead of the small free fraction that is usual.
Binding proteins: why they matter
This section is the key to understanding why the compound demands caution.
The IGFBPs are not inert packaging. They do three jobs:
- Regulated reservoir. They keep IGF-1 available and release it in a controlled way.
- Access control. They limit which tissues see how much, and when.
- Protection against excess signal. They buffer peaks.
A molecule that evades that system evades its regulation too. It is not only that it lasts longer: it acts outside the mechanism the body uses to control how much signal reaches where.
That is exactly the difference with the secretagogues, which stimulate the body's own production and preserve feedback control.
| GH secretagogues | IGF-1 LR3 | ||
|---|---|---|---|
| Where it acts | On the pituitary | Below the axis | |
| What it produces | Release of the body's own GH | Replaces the final mediator | |
| Resulting pattern | Pulsatile | Sustained | |
| Axis feedback | Preserved | Evaded | |
| Binding to carrier proteins | Not applicable | Sharply reduced | IGF-1 LR3 skips the entire axis and acts below it. |
The myth of local action at the injection site
The idea circulates that administering IGF-1 LR3 near a muscle would produce a localized effect in that muscle.
The biochemistry does not support it. The defining feature of the LR3 variant is precisely that it is not retained: because it does not bind the carrier proteins, it distributes through the circulation. A compound designed to stay free and circulate is the opposite of a compound that acts locally.
Evidence of local action does exist for IGF-1 in muscle physiology, but it refers to IGF-1 produced by the tissue itself, not to an administered molecule with a prolonged half-life.
Hypoglycemia and other considerations
This section is not optional, and it is the main reason this article exists.
IGF-1 shares structural homology with insulin and shows cross-activity at the insulin receptor. With high, sustained concentrations of a variant that carrier proteins do not sequester, that cross-activity can produce a drop in blood glucose.
Severe hypoglycemia is a potentially serious condition, it sets in fast, and its early symptoms (sweating, tremor, confusion) can be mistaken for something else.
Other considerations described for high, sustained exposure to IGF-1:
- Proliferative effects. IGF-1 is a growth factor: it promotes cell proliferation without selectivity. The epidemiological literature has explored the relationship between IGF-1 levels and the risk of certain cancers. That is not a claim of causality; it is a reason why an exogenous systemic growth factor is not a trivial compound.
- Fluid retention and joint pain, described with high IGF-1 exposure.
- Suppression of the body's own axis, through sustained negative feedback.
There are no safety trials in healthy people. All clinical characterization of IGF-1 comes from settings of diagnosed deficiency, under medical supervision, with the native molecule and not with the LR3 variant.
This article does not describe doses, schedules, or routes of administration, and that omission is deliberate.
WADA status and why it is on the list
IGF-1 and its analogues are named explicitly in section S2 of the prohibited list, among peptide hormones and growth factors. They are banned in and out of competition.
On top of that, since it is not approved by any regulatory authority, it also falls under category S0. As explained in the article on WADA, either route is enough on its own, and neither allows a therapeutic use exemption.
Batch analytical data is on its technical sheet.
What the evidence does not settle
Practically everything an informed assessment would require:
- Human pharmacokinetics of the LR3 variant: not published.
- Doses with a known relationship between exposure and effect: not established.
- Safety over any time frame in healthy people: no studies.
- Magnitude of hypoglycemia risk as a function of exposure: not characterized.
- Long-term consequences of a sustained systemic proliferative signal: unknown.
Faced with that many unknowns, the only defensible position is the conservative one, and it is the one this article adopts explicitly.
Frequently asked questions
Is IGF-1 LR3 a secretagogue?
No. Secretagogues prompt the body to produce its own growth hormone, preserving regulation of the axis. IGF-1 LR3 replaces the final mediator directly, skipping that control.
Can it be administered locally for a specific muscle?
The biochemistry of the LR3 variant argues against it: its defining feature is not binding the carrier proteins, which favors systemic distribution rather than local retention.
Why is hypoglycemia a concern?
Because IGF-1 shares homology with insulin and has cross-activity at its receptor. With high, sustained exposure, that activity can lower blood glucose, and severe hypoglycemia is a potentially serious condition.
Is it banned in sport?
Yes, by two routes: named in section S2 as a growth factor, and covered by S0 because it is not approved by any regulatory authority.
References
- Rajaram S, et al. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews, 1997;18(6):801–831. DOI: 10.1210/edrv.18.6.0321
- Tomas FM, et al. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochemical Journal, 1992;282(Pt 1):91–97. DOI: 10.1042/bj2820091
- Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinology and Metabolism Clinics of North America, 2012;41(2):425–443. DOI: 10.1016/j.ecl.2012.04.017
- Renehan AG, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. The Lancet, 2004;363(9418):1346–1353. DOI: 10.1016/S0140-6736(04)16044-316044-3)
- World Anti-Doping Agency. The Prohibited List — section S2. wada-ama.org
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.